Zhuleku, Evi
Antolin-Fontes, Beatriz
Borsi, Andras
Nissinen, Riikka
BravatĂ , Ivana
Barthelmes, Jennifer Norma
Lee, Jennifer
Passey, Alun
Wirth, Daniel
Maywald, Ulf
Bokemeyer, Bernd
Wilke, Thomas
Ghiani, Marco
Funding for this research was provided by:
Janssen-Cilag
Article History
Accepted: 6 March 2023
First Online: 20 March 2023
Declarations
:
: Due to the non-interventional, retrospective study design using fully anonymized data, ethics approval was not required for this study.
: Due to the non-interventional, retrospective study design using fully anonymized data, informed consent was not required for this study.
: Not applicable.
: EZ and BAF are employees of Cytel. The work of Cytel was sponsored by Janssen-Cilag. AB, RN, IB, JNB, JL, AP, and DW are employees of Janssen-Cilag. UM is an employee of AOK PLUS and declares no conflicts of interest. BB has received consulting fees from Abbvie, MSD, Shire, Ferring, UCB, Hospira, Takeda, Movetis, Shield Therapeutics, Pfizer, Biogen, Janssen, Hexal, Cellgene, Boehringer, Allergan, Galapagos, and Arena; provided speeches/lectures for Abbvie, Ferring, MSD, Merckle, Falk, HLR, UCB, Shield Therapeutics, Pfizer, Celltrion, Takeda, Janssen, Mundipharma, and Arena; and received research grants from Abbvie, Ferring, UCB, Given Imaging, Janssen, Takeda, Pfizer, and Galapagos. TW is a staff member of IPAM e.V. and has received honoraria from several pharmaceutical/consultancy firms, e.g., Novo Nordisk, Abbvie, Merck, GSK, BMS, LEOPharma, Bayer, Boehringer Ingelheim. MG is an employee of Cytel and staff member of IPAM e.V.